ASHEBORO, N.C., June 11, 2026 /PRNewswire/ -- Technimark, a global leader in plastic injection molding for healthcare, consumer packaging, and industrial markets, today announced...
Enhanced platform reflects continued momentum, user-informed innovation and growing adoption among attorneysBUFFALO, N.Y. and TALLAHASSEE, Fla., June 11, 2026 /PRNewswire/ -- M&T Bank (NYSE:MTB)...
STAMFORD, Conn., June 11, 2026 /PRNewswire/ -- Tronox Holdings plc (NYSE:TROX) ("Tronox" or the "Company"), the world's leading integrated manufacturer of titanium dioxide pigment, announced...
BOCA RATON, FL, June 11, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company with a treasury strategy built around accumulating and compounding Solana (SOL), today announced it will host its May 2026 Business Recap & Ask Me Anything (“AMA”) today, June 11, 2026, at 11:00 AM ET via X Spaces.
HOUSTON, TX, June 11, 2026 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ) Basin – today announced a series of actions that further strengthen the Company’s financial position, enhance liquidity, and continue to reduce potential shareholder dilution associated with the Company’s Series F Convertible Preferred Stock.
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
Mid-year update highlights strong execution across the Company's U.S. uranium operations, with an expected 1.6 million pounds of finished U3O8 produced from January through...
Greenfield facility in Madhya Pradesh to support 'Make in India' vision and strengthen Haleon's commitment to delivering better everyday healthStrategic oral health-focused site designed...
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.